PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

JAK2 kinase inhibitors and myeloproliferative disorders

(2010) Andrew T Chen et al.   CURRENT OPINION IN HEMATOLOGY

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

(2010) K. Van Roosbroeck et al.   HAEMATOLOGICA

Gastrointestinal stromal tumors

(2010) Bernadette Liegl-Atzwanger et al.   VIRCHOWS ARCHIV

Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer

(2009) Bharat B. Aggarwal et al.   Annals of the New York Academy of Sciences

Judging a proangiogenic cell by its cover

(2009) M. C. Yoder   BLOOD

Plasma-derived and recombinant FVIII

(2009) R. W. Herzog   BLOOD

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma

(2009) O. Ritz et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

(2009) Ehab Atallah et al.   Expert Review of Anticancer Therapy

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas

(2009) Cecile Meier et al.   MODERN PATHOLOGY

Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

(2009) Jacqueline Sayyah et al.   Current Oncology Reports

Therapeutic potential of JAK2 inhibitors

(2009) S. Verstovsek   Hematology-American Society of Hematology Education Program

NovelSSBP2-JAK2fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia

(2008) Jennifer L. Poitras et al.   GENES CHROMOSOMES & CANCER

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

(2008) A. Tzankov et al.   HAEMATOLOGICA

Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia

(2008) Kuan-Po Huang et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3

(2008) A Tzankov et al.   JOURNAL OF CLINICAL PATHOLOGY

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features

(2008) N C P Cross et al.   LEUKEMIA

Aberrant signal transduction pathways in myeloproliferative neoplasms

(2008) J Kota et al.   LEUKEMIA

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

(2008) O Kilpivaara et al.   LEUKEMIA

JAKandMPLmutations in myeloid malignancies

(2008) Ayalew Tefferi   LEUKEMIA & LYMPHOMA

JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies

(2008) William Vainchenker et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY